selected by Solvay Pharmaceuticals, Inc. for use in a multi-center cardiovascular drug research trial.

"We are pleased that Solvay Pharmaceuticals has chosen to incorporate the HDI/PulseWaveä CR-2000 Research System in this multi-site study," said Greg H. Guettler, president of HDI. "The use of the HDI/PulseWave™ CR-2000 in this trial further reinforces the ability of the CR-2000 System to provide information to pharmaceutical researchers that they otherwise would be unable to obtain."

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not predictions of actual future results. Actual results could differ materially from those anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 1999 Annual Report on Form 10-KSB under the caption "Risk Factors", as well as others not now anticipated. These risks and uncertainties include, without limitation, the Company’s ability to receive regulatory approval for its CVProfilor^® DO-2020 CardioVascular Profiling System; the availability of third-party reimbursements; and market acceptance of the Company’s products.

Hypertension Diagnostics, HDI/PulseWave™ and CVProfilor^® are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Contact: Greg H. Guettler, President